CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For...
(Source: CASI Pharmaceuticals Inc) ROCKVILLE, Md., Nov. 4, 2015 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet...
View ArticleEpizyme to Present New Scientific Data on the Role of HMT Inhibitors in...
(Source: Epizyme Inc) CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present...
View ArticleERYTECH announces data presentations at the American Society of Hematology...
(Source: ERYTECH Pharma SA) ba57e523-e7e8-45d3-93a7-15952086f562.pdf PRESS RELEASE ERYTECH announces data presentations at the American Society of Hematology 57th Annual Meeting Lyon (France), November...
View ArticleInfinity Provides Company Update And Reports Third Quarter 2015 Financial...
, Nov. 5, 2015 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2015 financial results and ongoing progress with its pipeline, including duvelisib, an...
View ArticleJuno Therapeutics to Present at the Credit Suisse 24th Annual Healthcare...
(Source: Juno Therapeutics Inc) SEATTLE--(BUSINESS WIRE)--Nov. 5, 2015-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Credit Suisse 24th Annual...
View ArticleImmune Design Announces Oral Presentation of G100 Product Candidate...
(Source: Immune Design Corp) SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today...
View ArticleUCB Presents Latest Research from Immunology Portfolio at American College of...
ATLANTA, Nov. 6, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is presenting 19 studies of CIMZIA® (certolizumab pegol) and...
View ArticleRoche showcases pharmaceuticals strategy and emerging new medicines (Roche...
(Source: Roche Holding AG) Basel, 5 November 2015 Roche showcases pharmaceuticals strategy and emerging new medicines Launches or pivotal data for up to eight new medicines planned in next three years...
View ArticleResults of Two Pivotal Baricitinib Trials to be Presented at 2015 American...
INDIANAPOLIS, Nov. 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces that detailed data for two phase 3 pivotal trials of the investigational medicine baricitinib in rheumatoid...
View ArticleGlobal Market Study on Next-Generation Antibody Therapeutics: Biosimilar...
NEW YORK, Nov. 5, 2015 /PRNewswire/ -- Next-generation antibody therapeutics refer to the improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Next-generation...
View ArticleBeat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American...
SAN DIEGO and TORONTO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the...
View ArticleResults of Two Pivotal Baricitinib Trials to be Presented at 2015 American...
(Source: Eli Lilly and Company) INDIANAPOLIS, Nov. 4, 2015/PRNewswire / -- Eli Lilly and Company (NYSE: LLY) announces that detailed data for two phase 3 pivotal trials of the investigational medicine...
View ArticleNew BNC105 Data To Be Presented in U.S. (Bionomics Limited)
(Source: Bionomics Limited) Microsoft Word - ASX741 BNO Updated MT_CT 2015_announcement ABN 53 075 582 740 ASX ANNOUNCEMENT 4 November 2015 BIONOMICS TO PRESENT PRECLINCAL DATA ON BNC105 AT...
View ArticleArgos Therapeutics to Participate in the 3rd International mRNA Health...
(Source: Argos Therapeutics Inc) DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ('Argos'), an immuno-oncology company focused on the development and...
View ArticleCompletion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for...
(Source: Hutchison China Meditech Limited) London: Friday, 30 October 2015: Hutchison China MediTech Limited ('Chi‑Med') (AIM: HCM) today announces that Hutchison MediPharma Limited ('HMP'), its drug...
View ArticleKaloBios to Reduce Workforce, Explore Strategic Alternatives
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will reduce its workforce as part of a plan to reduce operating costs....
View ArticleSangamo BioSciences To Present Data From ZFP Therapeutic Programs At Annual...
RICHMOND, Calif., Nov. 5, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that non-human primate data from its proprietary In Vivo...
View ArticleHalozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using...
SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous...
View ArticleHalozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using...
(Source: Halozyme Therapeutics Inc) SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. has dosed the first patient in a...
View ArticleFate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015...
(Source: Fate Therapeutics Inc) First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings...
View Article